Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.33 |
| ▸ | HTT | P42858 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | TPH1 | P17752 | 2/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.31 |
| ▸ | ACMSD | Q8TDX5 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2827246 | 1.00 | RXFP1 (0.33) | RXFP1HTTSMN1; SMN2POLBTDP1 | |
| SCHEMBL2826796 | 0.90 | MAPK1 (0.43) | RXFP1HTTSMN1; SMN2POLBMAPT | |
| SCHEMBL2826793 | 0.90 | MAPK1 (0.43) | RXFP1HTTSMN1; SMN2POLBMAPT | |
| SCHEMBL2826415 | 0.90 | PTGES (0.35) | RXFP1HTTSMN1; SMN2POLBTDP1 | |
| SCHEMBL2826413 | 0.90 | PTGES (0.35) | RXFP1HTTSMN1; SMN2POLBTDP1 | |
| SCHEMBL2829845 | 0.87 | HTT (0.34) | RXFP1HTTSMN1; SMN2POLBTDP1 | |
| SCHEMBL2829848 | 0.87 | HTT (0.34) | RXFP1HTTSMN1; SMN2POLBTDP1 | |
| SCHEMBL13287423 | 0.86 | ALDH1A1 (0.35) | RXFP1HTTSMN1; SMN2POLBTDP1 | |
| SCHEMBL2822434 | 0.84 | FFAR2 (0.32) | — | |
| SCHEMBL2822433 | 0.84 | FFAR2 (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8318928-B2 | Fused imidazole carboxamides as TRPV3 modulators | GLENMARK PHARMACEUTICALS, S.A. (CH) | 2012-11-27 | — | — | US | disclosed |
| US-20100152192-A1 | FUSED IMIDAZOLE CARBOXAMIDES AS TRPV3 MODULATORS | GLENMARK PHARMACEUTICALS S.A (CH) | 2010-06-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100152192-A1 | FUSED IMIDAZOLE CARBOXAMIDES AS TRPV3 MODULATORS | TRPV3, TRPV1, TRPV2 | RXFP1 921/4885HTT 2666/4885SMN1; SMN2 3907/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.